Alkaloid 2-propylquinolin-4-one (1, see Figure 1) was obtained in 76% yield, and 2-aryl analogues 22-
26, irrespective of the electronegativity of the substituents, were obtained in 64-74% yields. The
thienyl derivative 27 was obtained in 82% yield, and based on NMR data of the crude product, 3-
pyridyl analogue 28 was formed as well, but due to its extremely poor solubility this product could not
be isolated in sufficient purity. In both experiments involving alkenyl isoxazole precursors (6, 8),
clean reduction of the olefinic groups was observed, rendering phenylethyl compound 29 and alkaloid
2-pentylquinolin-4-one (2, see Figure 1) in good yields.
So the nickel boride-mediated reductive ring transformation of 5-(2-nitrophenyl)isoxazoles represents
a novel and effective approach to 2-substituted quinolin-4-ones. This reduction protocol is compatible
with a number of substituents located at aromatic rings (halogens, ethers, esters), further it is
compatible with thiophene rings, which are easily desulfurized by Raney nickel [29]. However,
conjugated and isolated olefinic bonds are gently reduced by this reagent. In this respect, the nickel
boride method is fairly complementary to the reduction with iron in acidic medium.
In conclusion we could demonstrate that the hitherto only rudimentarily investigated iron-mediated
reductive ring transformation of 5-(2-nitrophenyl)isoxazoles to 2-substituted quinolin-4-ones has some
potential applications in the synthesis of target compounds bearing olefinic residues, and further we
introduced nickel boride mediated transformations as a novel, cheap and easy-to-perform approach to
quinolin-4-ones.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in the online version, at
References
[1] T.D. Gootz, K.E. Brighty, Med. Res. Rev. 16 (1996) 433-486.
[2] E.D. Deeks, Drugs 74 (2014) 687-697.
[3] (a) S. Heeb, M.P. Fletcher, S.R. Chhabra, S.P. Diggle, P. Williams, M. Cámara, FEMS Microbiol.
Rev. 35 (2011) 247-274; (b) M.F. da Silva, M.S. Soares, J.B. Fernandes, P.C. Vieria, Alkaloids Chem.
Biol. 64 (2007) 139-214.
[4] S. Wagner, R. Sommer, S. Hinsberger, C. Lu, R.W. Hartmann, M. Empting, A. Titz, J. Med.
Chem. 59 (2016) 5929-5969.
[5] A.A. Wube, A. Hufner, C. Thomaschitz, M. Blunder, M. Kollroser, R. Bauer, F. Bucar, Bioorg.
Med. Chem. 19 (2011) 567-579.
[6] A. Monastyrskyi, D.E. Kyle, R. Manetsch, Curr. Top. Med. Chem. 14 (2014) 1693-1705.
[7] Y.H. Chang, J.S. Yang, S.C. Kuo, J.G. Chung, Anticancer Res. 29 (2009) 3139-3148.
[8] T. Mori, T. Yamashita, K. Furihata, K. Nagai, K. Suzuki, Y. Hayakawa, K. Shin-Ya, J. Antibiot.
60 (2007) 713-716.
[9] K. Kamigiri, T. Tokunaga, M. Shibazaki, B. Setiawan, M. Morioka, K.-I. Suzuki, R.M.
Rantiatmodjo, J. Antibiotics 49 (1996) 823-825.
[10] C. Agier, M. Bury, J. Aquette, R. Hocquemiller, P.G. Waterman, Nat. Prod. Res. 21 (2007) 698-
703.
[11] S.J. Wratten, M.S. Wolfe, R.J. Andersen, D.J. Faulkner, Antimicrob. Agents Chemother. 11
(1977) 411-414.
[12] A. Naeem, S.L. Badshah, M. Muska, N. Ahmad, K. Khan, Molecules 21 (2016) 268.
[13] A.A. Boteva, O.P. Krasnykh, Chem. Heterocycl. Comp. 45 (2009) 757.
[14] (a) D.V. Dar'in, P.S. Lobanov, Russ. Chem. Rev. 84 (2015) 601-633; (b) F. Bracher, Mini-Rev.
Org. Chem. (2019) in press; doi: 10.2174/1570193X16666181204122143.